

August 11, 2026

Senator Tim Sheehy
United States Senate
Russell Senate Office Building
Suite 124
Washington, DC 20510

Dear Senator Sheehy,

Healthcare costs continue to rise for American patients, and millions of families across the country are looking to Congress and this Administration for real solutions.

For decades, high-income nations — including Germany, France, Italy, Switzerland, Canada, and Japan — have used price controls, market access barriers, and regulatory practices to shift the cost of American and, indeed, global pharmaceutical innovation onto U.S. families. The result is a system where American patients subsidize the healthcare costs of some of the wealthiest countries in the world, while the treatments they help fund often remain out of reach at home. This arrangement has gone on far too long, and is getting worse through recent actions in Germany to double-down on unfair price controls and the European Union reducing IP rights on pharmaceutical innovation.

That is why the undersigned organizations write in strong support of your USTRx Act. Your legislation represents a commonsense, market-based solution to restore fairness in global pharmaceutical trade — one that protects American patients today and preserves the innovation ecosystem they will depend on tomorrow.

The USTRx Act is the right approach. It deploys existing trade tools and diplomatic mechanisms to hold foreign governments accountable for practices that have disadvantaged American patients for far too long. American pharmaceutical companies deliver life-saving cancer therapies, vaccines, and breakthrough treatments that patients around the world depend on. Sustaining that engine requires R&D investment and a strong regulatory and policy environment that encourages risk. When foreign governments exploit American R&D through price suppression, they are not just shorting U.S. companies. They are burdening American families who depend on cures.

New national polling commissioned by Americans for Health Excellence and conducted by McLaughlin & Associates confirms that the American public is squarely behind this effort. A survey of 2,000 likely voters found that nearly three-quarters say it is time for other countries to pay their fair share for American medicines. Eighty-one percent of voters back using trade negotiations to demand fair pricing from foreign nations.

The USTRx Act would lower costs, promote fairness, and preserve America's global leadership in medical innovation. We are proud to stand with you in this effort and urge your colleagues to join us in advancing this legislation.

Respectfully submitted,

Brad Wenstrup, DPM
Executive Director, Americans for Health Excellence

Joel White
President, Council for Affordable Health Coverage

Priscilla VanderVeer
Executive Director, No Patient Left Behind

Jeremy Snively
Director of Regulatory Affairs, Association of American Physicians and Surgeons

Saul Anuzis
President, 60 Plus Association

Rebecca Weber
Chairwoman, Association for Mature American Citizens Action



COUNCIL FOR AFFORDABLE
HEALTH COVERAGE



[Polling conducted by McLaughlin & Associates, March 10–14, 2026.](#) National survey of 2,000 likely general election voters. Margin of error $\pm 2.2\%$ at the 95% confidence interval.

August 11, 2026

Representative Jodey Arrington
United States House of Representatives
1107 Longworth HOB
Washington, DC 20515

Dear Representative Arrington,

Healthcare costs continue to rise for American patients, and millions of families across the country are looking to Congress and this Administration for real solutions.

For decades, high-income nations — including Germany, France, Italy, Switzerland, Canada, and Japan — have used price controls, market access barriers, and regulatory practices to shift the cost of American and, indeed, global pharmaceutical innovation onto U.S. families. The result is a system where American patients subsidize the healthcare costs of some of the wealthiest countries in the world, while the treatments they help fund often remain out of reach at home. This arrangement has gone on far too long, and is getting worse through recent actions in Germany to double-down on unfair price controls and the European Union reducing IP rights on pharmaceutical innovation.

That is why the undersigned organizations write in strong support of your USTRx Act (H.R. 4780). Your legislation represents a commonsense, market-based solution to restore fairness in global pharmaceutical trade — one that protects American patients today and preserves the innovation ecosystem they will depend on tomorrow.

The USTRx Act is the right approach. It deploys existing trade tools and diplomatic mechanisms to hold foreign governments accountable for practices that have disadvantaged American patients for far too long. American pharmaceutical companies deliver life-saving cancer therapies, vaccines, and breakthrough treatments that patients around the world depend on. Sustaining that engine requires R&D investment and a strong regulatory and policy environment that encourages risk. When foreign governments exploit American R&D through price suppression, they are not just shorting U.S. companies. They are burdening American families who depend on cures.

New national polling commissioned by Americans for Health Excellence and conducted by McLaughlin & Associates confirms that the American public is squarely behind this effort. A survey of 2,000 likely voters found that nearly three-quarters say it is time for other countries to pay their fair share for American medicines. Eighty-one percent of voters back using trade negotiations to demand fair pricing from foreign nations.

The USTRx Act would lower costs, promote fairness, and preserve America's global leadership in medical innovation. We are proud to stand with you in this effort and urge your colleagues to join us in advancing H.R. 4780.

Respectfully submitted,

Brad Wenstrup, DPM
Executive Director, Americans for Health Excellence

Joel White
President, Council for Affordable Health Coverage

Priscilla VanderVeer
Executive Director, No Patient Left Behind

Jeremy Snavelly
Director of Regulatory Affairs, Association of American Physicians and Surgeons

Saul Anuzis
President, 60 Plus Association

Rebecca Weber
Chairwoman, Association for Mature American Citizens Action



COUNCIL FOR AFFORDABLE
HEALTH COVERAGE



[Polling conducted by McLaughlin & Associates, March 10–14, 2026.](#) National survey of 2,000 likely general election voters. Margin of error $\pm 2.2\%$ at the 95% confidence interval.